Eli Lilly and Company News Releases

Full results from EMPERIAL exercise ability trials presented

RIDGEFIELD, Conn. and INDIANAPOLIS, June 19, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance ® (empagliflozin) in
favicon
investor.lilly.com
investor.lilly.com
Create attached notes ...